See the DrugPatentWatch profile for epclusa
What happens if you miss a dose of Epclusa (sofosbuvir/velpatasvir)?
Epclusa is a fixed-dose combination antiviral used to cure chronic hepatitis C. Missing a dose can lower the total amount of medicine you take that day, which may make it harder to keep the virus suppressed consistently. Skipping doses can increase the chance that treatment is less effective or that you may need to extend treatment, depending on how often you miss doses.
What should you do if you realize you missed a dose?
Use the timing of your next dose to decide what to do:
- If you remember soon after the missed dose (and it is still close to the scheduled time), take the missed dose when you remember.
- If it is close to the time for your next scheduled dose, skip the missed dose and take the next dose at the regular time.
- Do not take two doses at once to make up for a missed dose.
Can missing one dose cause immediate problems?
Most people do not feel immediate effects from a single missed dose. The main concern is staying consistent across the full course. The risk is more about overall adherence than about a single day.
If you miss multiple doses, what changes?
If you miss more than one dose, the concern shifts from short-term inconsistency to reduced adherence over time. That can affect the likelihood of cure. Contact your prescriber or pharmacist for guidance, since they may want to review how many doses were missed and whether any adjustments are needed.
When should you contact your doctor or pharmacist?
You should reach out if:
- You missed several doses in a row
- You are unsure whether to take a missed dose
- You have vomited shortly after taking Epclusa and aren’t sure whether to repeat a dose (ask your pharmacist for advice on timing)
- You are having trouble staying on schedule
How to prevent future missed doses
Setting a daily reminder (phone alarm, pillbox, or calendar) and taking Epclusa at the same time each day can reduce missed doses and help you finish the course as prescribed.
Sources: None provided.